The studies examined SIMPONI’s ability to induce and maintain remission in patients with moderate to severe ulcerative colitis.
The study found that SIMPONI was able induce and maintain remission in a higher percentage of patients when compared to the placebo group. SIMPONI is designed as a treatment for patients who have failed to respond to conventional treatments.
More Articles on Gastroenterology:
Forecasting the Demand for Colonoscopy: 4 GI Physicians Weigh In
8 Statistics on Irritable Bowel Disease
2014 CPT Code Update: GI/Endoscopy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
